It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Atypical respiratory viruses (ARVs) are a diverse group of pathogens that cause respiratory infections through less common mechanisms or in unique epidemiological patterns, unlike the typical viruses like respiratory syncytial virus, influenza and human rhinoviruses. They sometimes present as unusual respiratory illnesses in vulnerable populations with near-fatal outcomes. Several viruses are involved, such as Human metapneumovirus (HMPV), Human Bocavirus (HBoV), Enteroviruses (EVs), Parechovirus (PeV) and Influenza C virus (ICV). This review was done to shed light on ARVs and their possible role in respiratory illness or infections based on studies in Sub-Saharan Africa from 2013 to 2023.
Methods
We systematically reviewed atypical causes of respiratory virus infections in Sub-Saharan Africa (SSA) in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. We searched PubMed, Web of Science, Google Scholar and Cochrane Library to include studies published from 2013 to 2023 with reports on ARV. The protocol was registered in PROSPERO (ID: CRD42024611183).
Results
The review covered 46 SSA countries, with five eligible for the systematic review. The search yielded 548 publications, with only six studies meeting the inclusion criteria. Studies included children and individuals of all age groups. The prevalence of ARVs detected in SSA was as follows: HMPV pooled prevalence was 1.52% (95% CI: 1.07–2.00), EVs pooled prevalence was 15.0% (95% CI: 14.1–15.9), HBoV prevalence was 0.4%, PeV was 20%, and ICV was 1.3% in individuals with respiratory tract infection(s).
Conclusion
Our findings suggest testing or diagnostics for ARV infections are very low in SSA. Therefore, surveillance of people suffering from respiratory tract infections, which is lacking, needs to be improved to monitor the prevalence of ARVs and the role they play in respiratory disease outcomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer